58685-78-2

Usage

Uses

Used in Organic Synthesis:
2-(dimethylamino)-2-phenylacetic acid (hydrochloride salt) is used as a reagent in organic synthesis for its amine and carboxylic acid functional groups, enabling it to participate in a wide range of chemical reactions.
Used in Pharmaceutical Industry:
2-(dimethylamino)-2-phenylacetic acid (hydrochloride salt) is used as a pharmaceutical intermediate for the production of various pharmaceutical drugs, leveraging its medicinal properties to contribute to the development of new therapeutic agents.
Used in Medicinal Applications:
2-(dimethylamino)-2-phenylacetic acid (hydrochloride salt) is used as a potential treatment for medical conditions such as depression and anxiety, due to its studied effects on these conditions.

Upstream product

• 4870-65-9 2-bromophenylacetic acid 
• 124-40-3 dimethyl amine 
• 611-74-5 N,N-dimethylbenzamide 
• 6319-70-6 ethyl α-N,N-dimethylphenyl acetate 

Relevant academic research and scientific papers

TRPV1 agonist, preparation method and application thereof

The present invention relates to a compound represented by a formula I, a stereoisomer, a tautomer, a solvate, a polymorph or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the compound, and a preparation method and a medical use of the compound, wherein the structure of the formula I is shown in the specification.

Iridium-Catalyzed Reductive Strecker Reaction for Late-Stage Amide and Lactam Cyanation

A new iridium-catalyzed reductive Strecker reaction for the direct and efficient formation of α-amino nitrile products from a broad range of (hetero)aromatic and aliphatic tertiary amides, and N-alkyl lactams is reported. The protocol exploits the mild and highly chemoselective reduction of the amide and lactam functionalities using IrCl(CO)[P(C6H5)3]2 (Vaska's complex) in the presence of tetramethyldisiloxane, as a reductant, to directly generate hemiaminal species able to undergo substitution by cyanide upon treatment with TMSCN (TMS=trimethylsilyl). The protocol is simple to perform, broad in scope, efficient (up to 99 % yield), and has been successfully applied to the late-stage functionalization of amide- and lactam-containing drugs, and naturally occurring alkaloids, as well as for the selective cyanation of the carbonyl carbon atom linked to the N atom of proline residues within di- and tripeptides.

Discovery of inhibitors of the mitotic kinase TTK based on N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)-acetamides and carboxamides

TTK kinase was identified by in-house siRNA screen and pursued as a tractable, novel target for cancer treatment. A screening campaign and systematic optimization, supported by computer modeling led to an indazole core with key sulfamoylphenyl and acetamido moieties at positions 3 and 5, respectively, establishing a novel chemical class culminating in identification of 72 (CFI-400936). This potent inhibitor of TTK (IC50 = 3.6 nM) demonstrated good activity in cell based assay and selectivity against a panel of human kinases. A co-complex TTK X-ray crystal structure and results of a xenograft study with TTK inhibitors from this class are described.

KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME

The present teachings provide a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. Also described are a pharmaceutical composition and method of use thereof.